Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

Summary

This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab. Study Hypothesis: Mecamylamine could be effective in the treatment of neovascular AMD.

Timeline

Start

2008-05

Primary completion

2010-04

Completion

2010-05

Drugs

Indications